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Abstract: The identification of genes responsible for causing cancers from gene 
expression data has had varied success. Often the genes identified depend on the methods 
used for detecting expression patterns, or on the ways that the data had been normalized 
and filtered. The use of gene set enrichment analysis is one way to introduce biological 
information in order to improve the detection of differentially expressed genes and 
pathways. In this paper we show that the use of network models while still subject to the 
problems of normalization is a more robust method for detecting pathways that are 
differentially overrepresented in lung cancer data. Such differences may provide 
opportunities for novel therapeutics. In addition, we present evidence that non-small cell 
lung carcinoma is not a series of homogeneous diseases; rather that there is a heterogeny 
within the genotype which defies phenotype classification. This diversity helps to explain 
the lack of progress in developing therapies against non-small cell carcinoma and suggests 
that drug development may consider multiple pathways as treatment targets. 








In comparison to other cancers, over the last 30 years there has been little progress in the median 
survival time of lung cancer patients [1]. The median survival rate remains at around 3 months. Lung 
cancer cases account for about 13% of the total number of cancer cases diagnosed each year. It is also an 
increasingly significant cause of mortality in developing countries where there are a higher proportion of 
smokers [2]. Non-small cell lung carcinoma (NSCLC) is the most common form of bronchial tumor. 
Histological analysis of the tumors can divide them into two major sub-groups, adenocarcinoma and 
squamous cell carcinoma [3]. Some cases do not fall clearly into either of the sub-groups and so these 
are assigned to having a mixed morphology. Outside of these two main groupings there are also a 
small number of other rare histological groups.  
Microarrays can contribute to the treatment and therapy of NSCLC in two important ways. The first 
is by allowing earlier detection of the tumors through the use of biomarkers [4]. The essential feature 
of a biomarker is that it must provide an accurate method for detecting the disease, by having a high 
sensitivity and high specificity. Another important factor is that biomarker detection should be 
non-invasive. This is particularly important in lung cancer as you do not want to have to take samples 
of lung tissue itself and so biomarkers need to be available for either breath samples or blood samples. 
The second way that microarrays can contribute to the treatment of NSCLC is by identifying genes 
that are differentially expressed in the tumors and that could therefore be a target for new anti-cancer 
drugs. In this case the focus for the gene expression is the tumor tissue itself compared to normal lung 
tissue. Recently a number of large-scale studies have been under-taken to understand the factors involved 
in tumor progression [5–7]. These studies have used a variety of genomic, transcriptomic and 
proteomic methods and have identified, copy number variation, mutation and DNA methylation as 
well as changes in gene expression as differentiating between healthy lung tissue and tumors.  
One of the past difficulties in identifying genes that are important in determining cancer progression 
(“oncogenes”) has been the large number of differentially expressed genes. Microarray data is often 
noisy, and there is almost always a lack of technical replicates [8–10] One of the best known examples 
of microarray analysis is the diffuse large B-cell lymphoma study by Alizadeh et al. [11]. The data 
from this study has been used in a number of subsequent re-analyses, which have produced differing 
results. One study even suggested that computationally the data was inadequate for resolving the 
problem of identifying the significant genes [12]. This is a fundamental problem when you have high 
dimensional data, where a large number of variables produce a small number of outcomes. In this case 
a large number of gene expression values contribute to a small number of phenotypes (either being a 
tumor cell or not being a tumor cell). As an absolute minimum the number of biological samples 
should to exceed the number of independent variables. In the case of microarrays the genes are not 
expressed independently and so removing genes that show high degrees of correlation, and genes that do 
not vary at all between all of the different phenotypes can reduce the number of variables. This is why it 
is usual to perform a gene filtering step in microarray analysis in order to reduce the number of genes 
that are considered for testing for differential expression [13,14]. The problem is that this filtering can 
be rather arbitrary and might have an effect on the results of the analysis [15,16]. It would be better to 
use the complete dataset with appropriate corrections for multiple statistical tests. Another factor in the 
processing of the microarray data that has been shown to affect the results is normalization of the 
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samples. Once a set of differentially expressed genes has been identified these are often then reduced 
further by the use of gene set enrichment analysis (GSEA), to show which functional annotations are 
significantly up or down regulated [17]. An alternative to using GSEA, is to use a network based 
approach using data from biological pathways. 
In this paper seven publicly available datasets for NSCLC are reanalyzed and a network based 
analysis is carried out using the pathways from the Reactome database [18]. 
2. Experimental Section 
A search for NSCLC and organism Homo sapiens, in the ArrayExpress database yielded 223  
datasets [19]. The search was then refined to only include Affymetrix data. This reduced the number of 
datasets to 115. From these six datasets were chosen where the study looked only at NSCLC, it was a 
transcriptome profiling array and the number of samples was above 40. The datasets used in the study 
are listed in Table 1. In total there are 669 arrays in the combined data. 
Table 1. Datasets from ArrayExpress used in the data analysis. 
Accession Title Number of Arrays Date 
E-GEOD-6044 [20] Transcription profiling of human lung cancers 47 14 June 2008 
E-GEOD-18842 [21] Transcription profiling of NSCLC 91 1 October 2010 
E-GEOD-19188 [21] Transcription profiling of human lung cancer 156 28 May 2010 
E-GEOD-40275 [22] 
Gene expression of normal lung tissue and 
patients with SCLC or NSCLC 
84 25 August 2012 
E-GEOD-43458 [23] 
Gene expression profiling of lung 
adenocarcinomas and normal lung 
110 6 August 2013 
E-GEOD-50081 [24] 
Validation of histology independent 
prognostic signature for early stage NSCLC 
181 22 September 2013 
All of the analysis was carried out using R version 3.1.0 and Bioconductor version 2.14, using 
R-studio version 0.98 as a graphical user interface [25,26]. Quality checking of the arrays was not 
carried out, as the objective of the study was to test the robustness of the analysis. The data from 
HGU133aplus2 and HGFocus arrays was normalized using rma, gcrma and farms as described 
previously [16]. The E-GEOD-40725 is an exon dataset and could only be normalized using rma and 
the E-GEOD-43458 dataset could only be normalized with rma and farms. This is because feature 
tables for the other normalization methods are not available for some array designs. After normalization 
differential expression was calculated using limma for the multiple testing correction and Bayesian 
fitting on the complete dataset [27]. Pathway analysis was carried out against the Reactome database 
using ReactomePA [28]. 
3. Results and Discussion 
Some of the datasets had a very large number of differentially expressed genes. In the cases of  
E-GEOD-19188, E-GEOD-40725 and E-GEOD-50081 it was necessary to reduce the number of 
differentially expressed genes before running ReactomePA as the large number of genes had a 
negative effect on the algorithm finding any enriched pathways. In the cases of the E-GEOD-18842 
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and EG-GEOD-43458 datasets although there are a large number of differentially expressed genes 
these come from a small number of pathways, and so the pathway analysis could be carried out without 
the use of a cut-off. A plot of the adjusted p-value for the differential expression shows a long almost 
horizontal region before a sharp rise and then a steady linear increase (Figure 1). 
Figure 1. A plot of the adjusted p-values for the top scoring probes from the differential 
expression analysis between adenocarcinoma and squamous cell carcinoma in the  
E-GEOD-50081 dataset. 
 
From the graph the point where the adjusted p-value starts to rise from the horizontal is around 
2000 probes and so this was used as a limit on the number of differentially expressed genes in the 
problem datasets, except in the case of the normal vs. small-cell carcinoma comparison in dataset 
E-GEOD-40725 where a cut-off of 1500 was needed. 
3.1. The Effect of Normalization on the Number of Differentially Expressed Genes 
Table 2 shows the numbers of differentially expressed probes and genes for the different datasets.  
In some datasets there are multiple sub-groups and so these datasets have multiple comparisons in 
order to determine the variation in expression levels. It is also important to note that the number of 
genes identified by their EntrezID number is larger than the number of probes identified on the array. 
This is because there is a one-to-many relationship between the probes and EntrezID. This is far from 
ideal as this means that there are cross-gene effects in the array. 
From the table it is clear that the method used for normalization makes a difference to the number 
of differentially expressed genes and sometimes this can be quite large, amounting to over 1000 genes 
or about 20% of the total number. This could have a significant impact on any subsequent gene set 
enrichment analysis. 
There is also a general trend to a larger number of differentially expressed genes in the larger 
datasets. This reflects the higher power (improved sensitivity) of larger datasets, and the much smaller 
E-GEOD-6044 has a particularly small number of variable genes. However, the p-value distribution 
(Figure 1) also suggests that in the larger datasets noise is becoming an issue and that there are a large 
number of supposedly differentially expressed genes might be an artifact of those datasets. The 
E-GEOD-18842 and E-GEOD-43458 datasets both perform very well in the subsequent pathway 
analysis compared to the datasets where it was necessary to introduce a cut-off to reduce the number of 
genes being considered. Both of those datasets contained only two sub-groups and the division of the 
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data into further sub-groups unless these were part of the original experimental design is highly 
controversial and likely to result in an increased number of false positives. Only the E-GEOD-50081 
dataset suggests that there are a large number of differentially expressed genes between 
adenocarcinoma and squamous cell carcinoma, but this dataset was specifically created in order to ask 
this question. 
Table 2. The number of differentially expressed probes and genes (EntrezIDs) between the 
two specified conditions for each of the datasets normalized using rma, gcrma and farms.  
In cases where the cut-off of 2000 probes was used the number of EntrezIDs are given for 
these cut-off values. 
Dataset Conditions 
Number of Probes Number of EntrezIDs 
rma gcrma farms rma gcrma farms 
E-GEOD-6044 Normal-Adenocarcinma 235 260 196 251 293 209 
 Normal-Small 556 554 482 591 603 516 
 Normal-Squamous 341 347 248 368 388 264 
 Adenocarcinoma-Squamous 763 556 579 821 593 622 
E-GEOD-18842 Normal-NSCLC 6497 5951 5520 6481 6028 5599 
E-GEOD-19188 Healthy-Tumor 29,727 20,904 17,242 31,998 22,636 18,741 
 Healthy-Tumor 2000 2000 2000 2135 2132 2110 
E-GEOD-40275 Normal-Adenocarcinoma 13,255   16,387   
  2000   2418   
 Normal-Small Cell 14,942   18,559   
  1500   1947   
 Normal-Metastatic 7132   8897   
  2000   2492   
 Normal-Squamous 11,543   14,339   
  2000   2455   
 Adenocarcinoma-Squamous 274   362   
 Adenocarcinoma-Metastatic 6619   8278   
  2000   2455   
E-GEOD-43458 Normal-Adenocarcinoma 12,800  7099 14,186  7734 
E-GEOD-50081 Adenocarcinoma-Squamous 7769 6227 6181 8393 6728 6643 
  2000 2000 2000 2121 2132 2148 
 Adenocarcinoma-Mixed 231 437 168 249 463 186 
 Squamous-Mixed 1 42 0 1 44 0 
3.2. Pathway Analysis 
A pathway enrichment analysis of the differentially expressed genes was carried out against the 
Reactome pathway database using the ReactomePA module. Like gene set enrichment analysis this 
produces a list of key terms, in this case pathways, and a p-value for the probability that the observed 
distribution of expression occurred by chance. The cut-off value for the pathway p-values was chosen at 
0.05. An example of the effect of normalization on the pathway analysis is given in Figure 2. 
In this case there are a large number of additional pathways after farms normalization, but the 
pathways identified by the rma normalized analysis are conserved in the farms normalized results. It is 
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possible that in this case farms normalization produces a dataset that is more sensitive to changes in 
pathway regulation, but it is also possible that a number of these pathways will be false positives. 
Figure 2. Pathway Analysis for E-GEOD-43458, Normal-Adenocarcinoma. (left) After 
rma normalization; (right) After farms normalization. 
 
3.2.1. Pathways that Are Differentially Expressed between Normal Lung Tissue and Tumors 
Two of the datasets E-GEOD-18842 and E-GEOD-19188 compare normal lung tissue to NSCLC or 
tumor tissue, respectively. Of these E-GEOD-18842 has a much better defined list of differentially 
expressed genes. Again this is going to partly be a result of the larger size of the dataset as this results in 
a much lower standard error in the expression levels of the comparison groups and an increase in power 
of the experiment, but noise is also a factor as the final list contains almost all of the genes on the array. 
A cut-off had to be used for E-GEOD-19188 and only the top 2000 genes were used for pathway analysis. 
From the E-GEOD-18842 the three different normalization methods produce a very similar pathway 
analysis. The rma and farms normalized data give identical pathway analysis and identify 16 significant 
pathways (Figure 3). The results for the gcrma normalized data contain 12 out of the 16 previously 
identified pathways: deposition of new CENPA-containing nucleosomes at the centromere; telomere 
maintenance; unwinding of DNA and nucleosome assembly are absent, and separation of sister chromatids; 
resolution of sister chromatid cohesion; E2F mediated regulation of DNA replication; mitotic 
metaphase and anaphase; mitotic anaphase; DNA strand elongation and G2/M checkpoints are added. 
The results from E-GEOD-19188 are less definitive (Figure 4). From the rma and gcrma normalized 
data over 40 pathways are identified as significant. There is considerable overlap between these two 
pathway sets with 37 of the top 40 pathways being conserved between the two analyses. The farms 
normalized data only yields 29 significant pathways and some of those identified are notably different 
from the other results, especially the pathways associated with erythrocytes that are absent from the 
other pathway analyses (O2/CO2 exchange in erythrocytes, hemostasis, erythrocytes take up oxygen 
and release carbon dioxide, erythrocytes take up carbon dioxide and release oxygen). Associations 
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between hemostasis, platelets and cancer were proposed in the 1980s, but these associations have only 
recently become the focus of renewed attention for pathway analysis [29–31]. 
Figure 3. Pathway Analysis for E-GEOD-18842, Normal-NSCLC (left) After rma 
normalization; (right) After gcrma normalisation. 
 
 
The overlapping pathways between the E-GEOD-18842 and E-GEOD-19188 contain many of the 
usual suspects, such as the control of mitosis and control of the cell cycle including checkpoints. The 
E2F mediated regulation of DNA replication has also been identified as important in a number of 
different cancers, as this transcription factor regulates cyclin E [32]. Two other pathways of interest are 
the Polo-like kinase mediated events and the activation of ATR in response to replication stress. 
Polo-like kinase (PLK1) is a DNA damage checkpoint and it has been a target for cancer therapy 
[33,34]. Ataxia-telangiectasia and Rad3-related protein (ATR) halts DNA replication when replication 
forks are stalled and need to be repaired. The absence of gene creates fragile sites in the chromosome. 
ATR has been targeted as a possible cancer preventative or in boosting the effectiveness of existing 
therapies [35,36]. 
Figure 4. Pathway Analysis for E-GEOD-19188, Healthy-Tumor (left) After rma 
normalization; (right) After farms normalization. 
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3.2.2. Pathways that Are Differentially Expressed between Normal Lung Tissue and Adenocarcinoma 
Three datasets have a comparison between normal lung tissue and adenocarcinoma: E-GEOD-6044, 
E-GEOD-40725 and E-GEOD-43458. Of these the E-GEOD-43458 dataset is the largest and it is the 
only one that was specifically targeted to adenocarcinoma.  
The smallest of these datasets is E-GEOD-6044. This array also used the hgfocus gene array and 
not the more complete hgu133a array. From the rma and farms normalized data less than 10 pathways 
were identified and these were: biological oxidation; axon guidance; hemostasis; platelet activation, 
signaling and aggregation; platelet degranulation; translation of GLUT4 to the plasma membrane; 
response to elevated platelet cytosolic Ca2+; L1CAM interactions; phase 1-functionalisation of 
compounds; membrane trafficking and extracellular matrix organization. It is noteworthy that none of 
these pathways were amongst those identified as differences between the normal and tumor tissues and 
that they are not involved in cell cycle or DNA regulation. Phase 1-functionalisation is the processing 
and export of proteins from the endoplasmic reticulum and the reactions involve cytochrome P-450. 
Sugar transporters have previously been identified as having a role in cancer [37]. The L1 cell adhesion 
molecule L1CAM is associated with invasive tumors and metastasis [38,39]. After gcrma normalization 
pathway analysis identifies over 40 significant pathways (Supplementary Figure S1). These include the 
DNA regulation, mitotic pathways and cell cycle pathways previously identified in the normal-tumor 
comparisons. It also includes the meiosis pathways, negative regulation of rRNA expression and amyloids. 
The E-GEOD-40275 dataset uses an exon array and so it can only be normalized using rma. The 
results of pathway analysis are very different from those for the E-GEOD-6044 dataset and the 
normal-tumor analysis. These include a number of cancer specific pathways involving mutants and 
also a group of pathways involved in mRNA regulation and processing (Figure 5). 
Figure 5. Pathway Analysis for E-GEOD-40275, Normal-Adenocarcinoma. 
 
The E-GEOD-43458 dataset could only be normalized with rma and farms as gcrma is incompatible 
with the array type used. The results from the pathway analysis have been shown in Figure 2. As stated 
above there is a large difference in the number of pathways identified between the two analyses, with 
many more differentially expressed pathways after farms normalization. Many of them are previously 
identified pathways involved in cell cycle regulation and mitosis. Amyloids appear in both of the 
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pathway analyses and they were identified in the gcrma normalized pathway analysis of E-GEOD-6044. 
Serum amyloid a protein has been known for some time to be a biomarker for lung cancer and 
nasopharyngeal cancer [40,41]. Signaling pathways including the Rho GTPases, Wnt and TCF are also 
present in the post-farms pathway analysis. These signaling pathways have previously been associated 
with cancer, although TCF has mainly been associated with colorectal cancers [42–46]. The L1CAM 
pathway is also identified as being significant in agreement with the results from E-GEOD-6044. 
3.2.3. Pathways that Are Differentially Expressed between Normal Lung Tissue and Squamous  
Cell Carcinoma 
Two datasets are available to compare the transcriptomes of normal lung tissue and squamous  
cell carcinoma, E-GEOD-6044 and E-GEOD-40275. The E-GEOD-6044 data shows a similar profile  
to the normal-adenocarcinoma pathway profile for E-GEOD-40275 including the TCF dependent 
signaling in response to Wnt (Supplementary Figures S2–S4). There are also shared pathways with the 
normal-adenocarcinoma analysis of the same dataset. The results suggest that squamous cell carcinoma 
has an affect on a more diverse range of pathways than adenocarcinoma. 
The E-GEOD-40275 normal-squamous cell carcinoma comparison identifies platelet associated 
pathways as well as RNA processing as the most important groups of differentiated pathways (Figure 6). 
These overlap with the pathways identified in the normal-adenocarcinoma comparison carried out  
with the same dataset and also the normal-adenocarcinoma pathway differences identified using the  
E-GEOD-6044 data. 
Figure 6. Pathway analysis for E-GEOD-40275, Normal-Squamous Cell Carcinoma. 
 
3.2.4. Pathways that Are Differentially Expressed between Adenocarcinoma and Squamous  
Cell Carcinoma 
From the previous analysis it is apparent that there is considerable overlap in the pathways that are 
differentially expressed in adenocarcinoma and squamous cell carcinoma. There are three datasets  
that allow direct comparison between the transcriptomes of the two NSCLC sub-types, E-GEOD-6044, 
E-GEOD-40275 and E-GEOD-50081 (this dataset was specifically created to compare gene expression 
between cancer sub-types). Table 2 shows that there are only a small number of differentially 
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expressed genes between the two NSCLC sub-types except in the E-GEOD-50081 dataset. It is 
therefore slightly surprising that after pathway analysis this large number of genes reduces to 13 
pathways: unwinding DNA; type I hemidesmosome assembly; telomere maintenance; SIRTS1 
negatively regulates rRNA expression; packaging of telomere ends; nucleosome assembly; metabolism 
of porphyrins; heme degradation; glucuronidation; DNA strand elongation; Deposition of new 
CENPA-containing nucleosomes at the centromere; condensation of prophase chromosomes and 
chromosome maintenance. 
The E-GEOD-6044 dataset has many fewer differentially expressed genes (although more than are 
differentially expressed between normal-adenocarcinoma and normal-squamous cell carcinoma).  
This produces a much more extensive list of pathways, with novel pathways involved in extra-cellular 
processes, such as extracellular matrix organization, cell-cell communication, cell-cell junction 
organization and immune system. The data however is very noisy and there is poor overlap between the 
results from pathway analysis after the three different normalization methods and so these results should 
be considered with some caution. 
Finally the E-GEOD-40275 also shows a small number of differentially expressed pathways. These 
agree with the extra-cellular pathways found in the E-GEOD-6044 results lending support to those 
findings, and also include new pathways involved in fatty acid triacylglycerol, and ketone body 
metabolism, as well as the metabolism of lipids and lipoproteins. There are also two pathways 
highlighted that are involved in the regulation of the peroxisome proliferator-activated receptor alpha 
(PPARA). There is some evidence that PPARA is associated with breast cancer but this is the first time 
it has been identified as involved in lung cancer although the gamma receptor has previously been 
identified and playing a role in inhibiting lung cancer cell growth [47,48]. 
4. Conclusions 
The analysis shows that there is a clear genetic demarcation between healthy lung tissue and 
NSCLC which survives different datasets and methods of normalization. The results for the different 
NSCLC phenotypes (adenocarcinoma and squamous cell carcinoma) are much less clear. A 
comparison of the pathways which are overrepresented between the NSCLC phenotypes with normal 
lung tissue provides a clear core of altered cellular functions. However, when comparing the NSCLC 
phenotypes themselves, it is not possible to draw a clear and consistent delineation between their 
transcriptomes across all of the datasets. Most of the common pathway differences between the NSCLC 
phenotypes concern extra-cellular processes, and these are more likely to be associated with metastasis 
than phenotype differentiation. A possible distinguishing feature is the lipid biosynthetic pathways 
identified in the E-GEOD-40275 dataset, but these pathways were not reproduced in the other datasets. 
The small numbers of pathways that seem to distinguish adenocarcinoma and squamous cell carcinoma 
suggests that the histological differences might not be as strongly represented at the genetic level. This 
result agrees with a previous study that has shown that there are distinct sub-groups within 
adenocarcinoma and a second study that suggested that there might be overlap in gene expression 
between the adenocarcinoma and squamous cell carcinoma groups, such that alternative sub-classes to 
those identified by histology might exist at the genetic level [16,49]. 
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Many of the pathways that have been identified as targets in this study have previously been 
associated with cancer, either in lung cancer or in other tissues. These include the regulation of cell cycle 
and mitosis. Regulation of rRNA expression by SIRT1 and of histone methylation by PRC2 as well as 
the WNT signaling pathways are specific targets that distinguish healthy and tumor cells. The Amyloid 
pathway is an interesting additional target, because of its association with other age related diseases. 
Future experiments need to focus on including a larger number of participants in order to sample 
disease diversity more effectively. Current studies have also not considered experimental repeats to 
reduce the effects of between sample variations. These are important when between subject variability is 
high because a component of this might be due to problems with experimental precision. In addition to 
new experimental results a complete meta-analysis of all of the available NSCLC data would improve 
the statistical power and reliability in predicting differentially expressed genes and pathways. This 
analysis would include the large datasets that are available from the Cancer Genome Atlas, which 
contain data for another 1000 cases. However, a serious challenge in incorporating these data is that 
they come from a number of alternative platforms and so combining them is difficult. 
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